 NGM Biopharmaceuticals Inc NASDAQ: NGM has amended and restated an agreement with Merck Co Inc NYSE: MRK to extend their ongoing collaboration through March 2024 with a narrower scope. The collaboration will focus primarily on developing treatments for retinal and cardiovascular metabolic CVM diseases, including heart failure. 